Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report)’s stock price was down 3.7% during mid-day trading on Friday. The stock traded as low as $3.85 and last traded at $3.85. 200 shares traded hands during mid-day trading, a decline of 88% from the average session volume of 1,720 shares. The stock had previously closed at $4.00.
Silence Therapeutics Trading Down 3.7%
The company has a 50-day moving average price of $4.05 and a two-hundred day moving average price of $2.58.
Silence Therapeutics Company Profile
Silence Therapeutics plc is a biotechnology company focused on developing medicines that use RNA interference (RNAi) to selectively reduce the production of disease-causing proteins. Its approach is designed to target specific messenger RNA molecules before they are translated into proteins, potentially enabling treatments for conditions that are difficult to address with conventional therapies.
The company’s proprietary mRNAi GOLD platform supports the design and delivery of small interfering RNA (siRNA) medicines, including compounds intended to target tissues outside the liver.
Further Reading
- Five stocks we like better than Silence Therapeutics
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
